CXL-1020

CXL-1020 is an investigational small molecule drug developed as a nitroxyl (HNO) donor for the treatment of acute decompensated heart failure. Nitroxyl, the reduced and protonated form of nitric oxide, enhances left ventricular contractility without increasing heart rate by modifying calcium cycling through the sarcoplasmic reticulum and increasing myofilament sensitivity to calcium. Mechanistically, CXL-1020 donates nitroxyl that stimulates sarcoplasmic reticulum Ca2+-ATPase (SERCA) via glutathiolation at cysteine 674, accelerating ATP-dependent Ca2+ uptake into the sarcoplasmic reticulum. It also interacts with ryanodine receptor 2 (RyR2), enhancing its opening probability and promoting Ca2+ release for myofilament activation. These actions improve both inotropy and lusitropy in failing hearts while avoiding increased arrhythmogenic risk or chronotropic effects seen with some other agents[1][4][5][6]. The drug is administered intravenously.